A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Recruiting · NCT07311200 · Interventional (participants receive a specific treatment) · Lead sponsor: InventisBio Co., Ltd
View the official record on ClinicalTrials.gov →Interventions studied
D-2570D-2570 Placebo
What this trial is about
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- The patient voluntarily participates in this study after full informed consent.
- The age is 18 years ≤ age ≤ 70 years, regardless of gender.
- Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
- SLEDAI-2K total score ≥ 8.
- On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.
Exclusion criteria
- History of infection as defined in the protocol.
- Any of the medical diseases or disorders listed in the protocol.
- Significant, uncontrolled or unstable disease in any organ.
Where it is running
1 location listed.
- Linfen Central Hospital - Linfen, Jiangxi, China